COVID-19 Safety Precautions: Find the Latest Visitor and Mask Policies. Learn More
A Multi-indication, Single-treatment Arm, Open-label Phase 2 Study of Regorafenib and Nivolumab in Combination in Patients with Recurrent or Metastatic Solid Tumors
In this trial, the researchers want to learn about regorafenib taken together with nivolumab in a small number of participants with different types of tumors. These include tumors in the head and neck, the esophagus, the pancreas, the brain, and the biliary tract. The biliary tract includes gall bladder and bile ducts.
Primary * To evaluate efficacy of the regorafenib and nivolumab combination by cohort Secondary * Evaluation of the additional efficacy measures of the regorafenib and nivolumab combination * To evaluate safety of the combination by cohort and overall
BAY 73-4506 (Regorafenib); BMS-936558 (Nivolumab); Nivolumab (Opdivo); Regorafenib (Stivarga)
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.